We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current VACBF market cap is 169.51M. The company's latest EPS is USD -0.1077 and P/E is -4.83.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 1.41M | 215.7M | 35.77M | 9.03M | 13.32M |
| Operating Income | -13.94M | 178.27M | -10.78M | -53.16M | -58.08M |
| Net Income | -13.7M | 149.77M | -9.41M | -42.74M | -35.15M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 33.39M | 230.03M | 265.56M | 221.48M | 208.19M |
| Total Liabilities | 5.76M | 51.18M | 71.5M | 64.46M | 36.93M |
| Total Equity | 27.63M | 178.85M | 194.06M | 157.02M | 171.26M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -10.49M | 180.27M | 1.16M | -20.7M | -96.62M |
| Investing | -9.06M | -6.02M | 10.75M | 11.05M | 7.04M |
| Financing | 25.87M | -289k | 20.44M | 360k | 44.59M |
| Market Cap | 169.51M |
| Price to Earnings Ratio | -4.83 |
| Price to Sales Ratio | 12.75 |
| Price to Cash Ratio | 1.05 |
| Price to Book Ratio | 0.99 |
| Dividend Yield | - |
| Shares Outstanding | 326.55M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | -67.15% |
| 52 Week High | 1.58 |
| 52 Week Low | 0.5191 |
| Spread (Intraday) | 4k (99.99%) |
| Company Name | Nykode Therapeutics AS (PK) |
| Address |
gaustadalleen 21 oslo NO-0349 |
| Website | https://www.nykode.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
